Alphamab Oncology (HKSE:09966) EBITDA Margin % : -0.40% (As of Jun. 2023)

Alphamab Oncology EBITDA Margin % Chart

Alphamab Oncology Semi-Annual Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EBITDA Margin %	Get a 7-Day Free Trial								-79.70	-211.24	-126.39	-0.40	-201.09

Competitive Comparison of Alphamab Oncology's EBITDA Margin %

For the Biotechnology subindustry, Alphamab Oncology's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alphamab Oncology's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alphamab Oncology's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Alphamab Oncology's EBITDA Margin % falls into.

Alphamab Oncology EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Alphamab Oncology's EBITDA Margin % for the fiscal year that ended in Dec. 2022 is calculated as

Alphamab Oncology's EBITDA Margin % for the quarter that ended in Jun. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alphamab Oncology  (HKSE:09966) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Alphamab Oncology EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Alphamab Oncology's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Alphamab Oncology (HKSE:09966) Business Description